Renaissance Technologies’s Milestone Pharmaceuticals MIST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$154K Buy
+129,705
New +$227K ﹤0.01% 2960
2023
Q3
Sell
-108,766
Closed -$310K 3932
2023
Q2
$310K Buy
108,766
+16,966
+18% +$64K ﹤0.01% 3111
2023
Q1
$362K Buy
91,800
+24,600
+37% +$89.9K ﹤0.01% 3036
2022
Q4
$266K Buy
+67,200
New +$354K ﹤0.01% 3278
2021
Q4
Sell
-26,400
Closed -$151K 4106
2021
Q3
$151K Sell
26,400
-81,154
-75% -$458K ﹤0.01% 3258
2021
Q2
$592K Sell
107,554
-108,846
-50% -$617K ﹤0.01% 2898
2021
Q1
$1.25M Buy
216,400
+52,400
+32% +$384K ﹤0.01% 2507
2020
Q4
$1.1M Buy
164,000
+148,900
+986% +$997K ﹤0.01% 2457
2020
Q3
$111K Buy
+15,100
New +$108K ﹤0.01% 3205
2020
Q2
Sell
-10,242
Closed -$19K 3648
2020
Q1
$19K Buy
+10,242
New +$177K ﹤0.01% 3375

Other funds holding MIST

Renaissance Technologies's MIST Position: Q1 2026 in Review

Renaissance Technologies opened a new position in Milestone Pharmaceuticals (MIST) in Q1 2026: 129,705 shares worth $154K. The stake represents ﹤0.01% of the portfolio and ranks #2960 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in MIST as recently as Q2 2023.

Renaissance Technologies first reported a position in MIST in Q1 2020 and has held it in 10 quarters since. The position peaked at $1.25M in Q1 2021. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Renaissance Technologies held 129,705 shares of Milestone Pharmaceuticals worth $154K as of Q1 2026.
  • Milestone Pharmaceuticals was a new Renaissance Technologies position in Q1 2026.
  • Milestone Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2960 holding.
  • Renaissance Technologies first reported a position in Milestone Pharmaceuticals in Q1 2020 and has held it in 10 quarters since.
  • Renaissance Technologies's Milestone Pharmaceuticals position peaked at $1.25M in Q1 2021.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.